Novel Drug Delivery Systems Market Reaches $187.53 Billion In 2026: Key Developments Shaping Expansion

Novel Drug Delivery Systems Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Novel Drug Delivery Systems Market Revenue Growth On Track For A 9.7% CAGR Through 2030

The market size for novel drug delivery systems has experienced significant growth recently. It is set to increase from $117.66 billion in 2025 to $129.45 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. This historical growth can be linked to the rising prevalence of chronic illnesses, the shortcomings of conventional drug delivery methods, the expanding scope of oncology and biologics pipelines, increased healthcare spending, and advancements in polymer and nanotechnology.

The novel drug delivery systems market size is anticipated to undergo significant expansion in the coming years. It is projected to reach $187.53 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. This growth over the forecast period can be attributed to a rise in personalized and precision medicine, an increasing need for targeted cancer treatments, heightened investment in pharmaceutical research and development, the expanding scope of biologics and biosimilars, and supportive regulations for advanced drug delivery technologies. Prominent trends expected during this period include the wider application of targeted and personalized drug delivery, growing acceptance of lipid and polymeric nanoparticles, an increase in long-acting and controlled release formulations, a stronger focus on non-invasive and patient-centric delivery methods, and accelerated research and development in combination and hybrid novel drug delivery systems platforms.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=79029085&type=smp&name=Novel%20Drug%20Delivery%20Systems%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Novel Drug Delivery Systems Market Expansion Drivers: What’s Shaping Future Growth?

The increasing prevalence of neurological disorders is projected to boost the growth of the novel drug delivery systems market moving forward. A neurological disorder such as stroke is defined as a medical condition characterized by the sudden loss of neurological function, occurring when the brain’s blood supply is disrupted, either by a blockage (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke), resulting in brain tissue damage and potentially enduring cognitive, sensory, or motor impairments. The rising occurrence of neurological disorders is primarily influenced by factors such as an aging populace, a greater prevalence of lifestyle-related conditions like hypertension, diabetes, and obesity, and heightened exposure to chronic stress and environmental risk factors. Novel drug delivery systems assist in managing these disorders by enabling targeted and controlled delivery of therapeutic agents across the blood-brain barrier. For example, in November 2024, figures from the National Health Service (NHS) England, a UK-based healthcare system, revealed that stroke admissions in England increased to 111,137 in 2023/24, with the 50–59 age group showing the sharpest rise at 12,533 cases. Therefore, the growing number of neurological disorder cases is propelling the expansion of the novel drug delivery systems market.

Novel Drug Delivery Systems Market Segmentation And Category Overview

The novel drug delivery systems market covered in this report is segmented –

1) By Formulation Type: Liposomes, Nanoparticles, Microspheres, Hydrogels, Dendrimers

2) By Mode Of Novel Drug Delivery System (NDDS): Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems

3) By Route: Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, Other Routes

4) By Therapeutic Area: Cancer, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Autoimmune Diseases

5) By End-User: Hospital, Specialty Clinics, Research Centers, Other End-Users

Subsegments:

1) By Liposomes: PEGylated Liposomes, Cationic Liposomes, Stealth Liposomes, Immunoliposomes

2) By Nanoparticles: Polymeric Nanoparticles, Lipid Nanoparticles, Metallic Nanoparticles, Nanocrystals

3) By Microspheres: Biodegradable Microspheres, Magnetic Microspheres, Radioactive Microspheres, Mucoadhesive Microspheres

4) By Hydrogels: Thermosensitive Hydrogels, Ph-Responsive Hydrogels, Injectable Hydrogels, Smart Hydrogels

5) By Dendrimers: PAMAM Dendrimers, PPI Dendrimers, Pegylated Dendrimers, Hybrid Dendrimers

Novel Drug Delivery Systems Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies in the novel drug delivery systems market are concentrating on developing inventive solutions, such as oral thin films, to improve patient adherence and therapeutic efficacy. An oral thin film is a drug delivery mechanism composed of a rapidly dissolving film strip applied in the oral cavity, engineered to release medication directly into the bloodstream via the mucosal membrane. For instance, in February 2024, CD Formulation, a US-based pharmaceutical formulation company, launched Oral Thin Film Technology. This product allows for quick drug absorption by bypassing gastrointestinal and liver metabolism, making it particularly suitable for patients with swallowing difficulties. It also supports accurate dosing and a faster onset of action, thereby enhancing treatment precision and convenience across diverse therapeutic applications.

Novel Drug Delivery Systems Market Top Companies Driving Competitive Growth

Major companies operating in the novel drug delivery systems market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Gilead Sciences, Amgen Inc, Teva Pharmaceutical Industries Ltd, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals, Samyang Holdings Corporation, Galen Limited, Catalent Inc, Evonik Industries AG

View The Full Novel Drug Delivery Systems Market Report:

https://thebusinessresearchcompany.com/report/novel-drug-delivery-systems-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Novel Drug Delivery Systems Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the novel drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novel drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model